We believe people living with poor mental health deserve treatments that work quickly, have long-lasting benefits and are tolerated well.
Neurocentrx is a growing biopharma company developing oral ketamine formulations for the treatment of mood disorders such as depression, bipolar depression and other mental health conditions.
We are working with medicine regulators to approve a new prescription form of ketamine as a rapid acting medicine to treat depression. We believe our immediate-release, abuse-deterrent formulation may be used in place of costly and time-consuming medical procedures, which currently prevent doctors from prescribing ketamine as a medication to treat depressed patients
Neurocentrx is a growing biopharma company developing a range of oral ketamine formulations for the treatment of mood disorders such as depression, anxiety, bipolar and other mental health conditions.
We are on a mission to provide an easy to administer and rapidly acting medicine for patients living with depression to use safely at home, thus alleviating some of the need for costly and time-consuming in-patient treatment.
Our Phase1 human trial with our partners at King’s College London completed successfully in early 2023 and we are now planning multiple Phase II/III studies for regulatory approval. You can find out more on these on our ‘Pipeline’ page and learn about our current investors on our Investors page.
Our intellectual property features diverse know-how and patents, including composition filings intended to fulfil FDA best practice requirements for abuse-deterrent formulations of controlled substance drug products.